Thrombin
Evicel, TachoSil, VeraSeal (thrombin) is an unknown pharmaceutical. Thrombin was first approved as Tachosil on 2004-06-08. It is used to treat hemorrhage in the USA. It has been approved in Europe to treat hemostasis and surgical hemostasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Evithrom, Recothrom, Thrombin-jmi, thrombocoll (discontinued: Evithrom)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Thrombin
+
topical (bovine)
Thrombin
+
topical (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Evithrom | Thrombin, Topical (Human) | Omrix Biopharmaceuticals | A-125247 RX | 2009-09-17 | 1 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| recothrom | Biologic Licensing Application | 2024-01-04 |
| tachosil | Biologic Licensing Application | 2025-02-11 |
| thrombin human | Biologic Licensing Application | 2009-09-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hemorrhage | MP_0001914 | D006470 | R58 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AE: Direct thrombin inhibitors
— B02: Antihemorrhagics
— B02B: Vitamin k and other hemostatics
— B02BC: Local hemostatics
— B02BC06: Thrombin
— B02BD: Blood coagulation factors
— B02BD30: Thrombin
Clinical
Clinical Trials
553 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 4 | 7 | 23 | 16 | 38 | 87 |
| Thrombosis | D013927 | — | — | 3 | 8 | 9 | 5 | 38 | 60 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | 2 | 5 | 3 | 35 | 44 |
| Hemostatic disorders | D020141 | — | — | — | 2 | 5 | 3 | 35 | 44 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 7 | 6 | 1 | 14 | 27 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | 1 | 3 | 2 | 17 | 23 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | 1 | 16 | 18 |
| Thromboembolism | D013923 | — | — | — | 3 | 2 | 3 | 10 | 17 |
| Surgical blood loss | D016063 | — | — | — | 1 | 4 | 4 | 7 | 16 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 4 | 5 | 3 | 4 | 15 |
Show 78 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | — | I82.40 | — | 6 | 7 | — | 14 | 24 |
| Embolism | D004617 | — | — | — | 1 | 3 | — | 12 | 15 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | — | 2 | — | 9 | 11 |
| Ulcer | D014456 | MPATH_579 | — | 3 | 2 | 3 | — | 3 | 10 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 3 | 3 | — | 2 | 8 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 2 | 2 | — | 4 | 7 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 2 | — | 3 | 5 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | — | 1 | — | 2 | 4 |
| Liver failure | D017093 | — | K72.9 | — | — | 2 | — | 2 | 4 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | 2 | — | 1 | 4 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | — | 2 | — | — | 4 | 6 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | 2 | 3 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | 2 | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | 2 | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | — | 2 |
| Transfusion reaction | D065227 | — | D69.51 | — | 1 | — | — | 1 | 2 |
| Blood transfusion | D001803 | — | — | — | 1 | — | — | 1 | 2 |
| Congenital heart defects | D006330 | — | Q24.9 | — | 1 | — | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | 1 | 2 |
| Pathologic processes | D010335 | — | — | — | 1 | — | — | — | 1 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 4 | 5 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | 1 | — | — | — | 2 | 3 |
| Virus diseases | D014777 | — | B34 | 1 | — | — | — | 1 | 2 |
| Corneal injuries | D065306 | — | — | 2 | — | — | — | — | 2 |
| Intraabdominal infections | D059413 | — | — | 1 | — | — | — | — | 1 |
| Intestinal fistula | D007412 | — | K63.2 | 1 | — | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | — | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | — | — | — | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 11 | 11 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 8 | 8 |
| Thrombophilia | D019851 | — | D68.59 | — | — | — | — | 6 | 6 |
| Disseminated intravascular coagulation | D004211 | — | D65 | — | — | — | — | 6 | 6 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 5 | 5 |
| Coagulation protein disorders | D020147 | — | — | — | — | — | — | 5 | 5 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 5 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 4 | 4 |
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 4 | 4 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | — | 4 | 4 |
Show 200 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Thrombin |
| INN | thrombin |
| Description | Thrombin (EC 3.4.21.5, fibrinogenase, thrombase, thrombofort, topical, thrombin-C, tropostasin, activated blood-coagulation factor II, blood-coagulation factor IIa, factor IIa, E thrombin, beta-thrombin, gamma-thrombin) is a serine protease, an enzyme that, in humans, is encoded by the F2 gene.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4UD9:H|Thrombin heavy chain
IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISM
LEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVL
QVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFY
THVFRLKKWIQKVIDQFGE
>4UD9:I|Hirudin-2
GDFEEIPEE(TYS)LQ
>4UD9:L|Prothrombin
EADCGLRPLFEKKSLEDKTERELLESYI |
Identifiers
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,669 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,307 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use